Federal Circuit Delivers Final Blow to Medical Device Patent in Arthrex Case

On July 9, the Federal Circuit issued a Rule 36 judgment, a procedural move that affirms the PTAB's rulings without a written opinion. Though such rulings are legally binding and final, they provide no insight into the court’s reasoning. Still, the judgment represents a significant win for Arthrex and reaffirms the strength of the PTAB's authority in reviewing and invalidating patent claims.

The disputed patents, while not publicly specified in detail in the judgment, involve surgical implant devices—a high-stakes area within the medical device market, where intellectual property can make or break competitive edge. Arthrex, known for developing innovative surgical anchors and fixation devices, had argued that the patents in question lacked novelty and were obvious in light of prior art.

This win is particularly notable given Arthrex's complicated history with the PTAB. In 2021, Arthrex was at the center of a landmark Supreme Court case (United States v. Arthrex Inc.), which found that the structure of the PTAB was unconstitutional because administrative patent judges (APJs) wielded too much power without sufficient oversight. That decision led to procedural reforms allowing the USPTO Director to review final PTAB decisions. Despite that backdrop, the current affirmation suggests that under the reformed system, the board’s decisions still carry considerable weight.

Industry watchers say this decision could have ripple effects, reinforcing the PTAB’s role as a powerful venue for invalidating weak patents in the highly competitive medtech space. For companies like Arthrex, it highlights how IPRs can be a potent strategy to eliminate legal obstacles and gain market advantage.

It’s also a reminder to patent holders that PTAB decisions—when upheld by the Federal Circuit—can be difficult to reverse. Given the costs and time involved in federal appeals, the affirmation via Rule 36 represents a practical final nail in the coffin for the disputed claims.